Literature DB >> 18588429

Half-lives of albumin and cholinesterase in critically ill patients.

Thomas Gamsjäger1, Lydia Brenner, Christian Sitzwohl, Christian Weinstabl.   

Abstract

BACKGROUND: Albumin and plasma cholinesterase are markedly reduced in critical illness. However, the plasma half-lives of these two proteins have only been determined in very limited numbers of patients mostly outside intensive care. Therefore, we determined the kinetics of decrease of albumin and cholinesterase in a large population of critically ill patients.
METHODS: Medical records of all patients of two university-affiliated surgical intensive care units during a time period of 8 years were retrospectively evaluated. To calculate the rate of fall, the first value in every episode of decreasing albumin or cholinesterase was arbitrarily set at 100% and the ensuing lower values were expressed as the respective fractions.
RESULTS: Records of 3591 patients were evaluated. Regression analysis exhibited an exponential evolution of albumin and cholinesterase over time with corresponding mean apparent plasma half-lives of 11.8 days [95% confidence interval (CI): 10.8-12.9] for albumin and 7.8 days (95% CI: 7.4-8.3) for cholinesterase.
CONCLUSIONS: These findings suggest that the apparent plasma half-lives of albumin and cholinesterase in critically ill surgical patients are considerably shorter than previously determined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588429     DOI: 10.1515/CCLM.2008.220

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  2 in total

1.  Levobupivacaine plasma concentrations following major liver resection.

Authors:  Anne-Eva Lauprecht; Frank A Wenger; Osama El Fadil; Martin K Walz; Harald Groeben
Journal:  J Anesth       Date:  2011-03-03       Impact factor: 2.078

2.  The impact of low serum cholinesterase levels on survival in patients with colorectal cancer.

Authors:  Yasuhiro Takano; Koichiro Haruki; Shu Tsukihara; Daisuke Ito; Hironori Kanno; Kyonsu Son; Nobuyoshi Hanyu; Ken Eto
Journal:  Int J Colorectal Dis       Date:  2022-03-15       Impact factor: 2.796

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.